Testosterone Cypionate for Injection, USP, 1,000 mg/10 mL (100 mg/mL), 10 mL Multiple Dose Vial (...
FDA Drug Recall #D-0787-2020 — Class II — January 14, 2020
Recall Summary
| Recall Number | D-0787-2020 |
| Classification | Class II — Moderate risk |
| Date Initiated | January 14, 2020 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Sun Pharmaceutical Industries, Inc. |
| Location | Cranbury, NJ |
| Product Type | Drugs |
Product Description
Testosterone Cypionate for Injection, USP, 1,000 mg/10 mL (100 mg/mL), 10 mL Multiple Dose Vial (NDC 62756-017-40), Rx only, Distributed by: Sun Pharmaceuticals, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceuticals, Industries, Ltd., Gujarat, India
Reason for Recall
cGMP Deviations; released lots were manufactured under similar manufacturing conditions to a previously rejected OOS Lot.
Distribution Pattern
Product was distributed throughout the United States.
Lot / Code Information
JKT0933A, JKT0935A, JKT1062A exp Mar-20; JKT1425A, JKT1483A exp Apr-20; JKT1575A, JKT1729A, JKT1730A, JKT1728A exp May-20 JKT2002A exp Jun-20; JKT3216A, JKT3217A exp Sep-20; JKT3589A, JKT3590A, JKT3626A exp Oct-20; JKT3864A, JKT3935A exp Dec-20
Other Recalls from Sun Pharmaceutical Industries, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1033-2020 | Class II | Doxycycline Capsules, USP, 100 mg, 50-count bot... | Mar 13, 2020 |
| D-1032-2020 | Class II | Doxycycline Capsules, USP, 75 mg, 100-count bot... | Mar 13, 2020 |
| D-1047-2020 | Class II | Atorvastatin Calcium Tablets, USP 40 mg, Rx onl... | Mar 9, 2020 |
| D-0788-2020 | Class II | Testosterone Cypionate for Injection, 2,000 mg/... | Jan 14, 2020 |
| D-0660-2020 | Class II | Sumatriptan Succinate Tablets, 100 mg packaged... | Dec 26, 2019 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.